Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Dynorphin B** is an endogenous opioid peptide derived from the precursor protein prodynorphin via cleavage by proprotein convertase 2. It is one of three major dynorphin peptides (alongside dynorphin A and neoendorphin) found in the central nervous system, particularly in regions such as the hypothalamus, medulla, pons, midbrain, and spinal cord[4][5]. Dynorphin B has the highest affinity for the **kappa opioid receptor (KOR)**, where it acts primarily as an agonist, eliciting inhibitory effects on neurotransmission and analgesia, but is also known to bind with lower affinity to mu and delta opioid receptors[1][5]. It can also exert effects via non-opioid pathways, including activation of protein kinase D (PKD) and dynamin-related protein 1 (DRP1), leading to mitochondrial fragmentation and dysfunction in certain cell types and mediating gene transcription in cell nuclei, particularly for cardiac lineage-associated genes (GATA-4 and Nkx-2.5)[2][3]. Its actions influence mood disorders, addiction behaviors, analgesia, dysphoria, stress responses, and mitochondrial dynamics.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dynorphin b.